Julie E. Chang, MD close
Julie E. Chang, MD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Julie E. Chang, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Chang is an associate professor of medicine within the division of hematology/oncology at the UW School of Medicine and Public Health. After graduating from Indiana University School of Medicine, she completed her internal medicine residency and hematology and oncology fellowships at the University of Wisconsin. Dr. Chang treats a wide range of cancers, but has special interest in lymphoma and complications of cancer involving the central nervous system. She is actively participating in further developing the Lymphoma Research Program at the University of Wisconsin Carbone Cancer Center.



Brain Tumor Care

Hematology (Leukemia, Lymphoma and Multiple Myeloma)

Hematology (non cancer)

Leukemia, Lymphoma, Multiple Myeloma


UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Hematology
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Wisconsin Hospital and Clinics, Madison, WI
Medical School Indiana University School of Medicine, Indianapolis, IN

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Dr. Chang is part of the UW Lymphoma Research Program, through which multiple clinical trials are focusing on developing improved treatment options for patients with lymphoma. Dr. Chang's research interests include lymphoma, experimental therapeutics and complications of cancer involving the central nervous system.

PubMed Articles
Evens AM Hong F Habermann TM Advani RH Gascoyne RD Witzig TE Quon A Ranheim EA Ansell SM Cheema PS Dy PA O'Brien TE Winter JN Cescon TP Chang JE Kahl BS A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. Clin Cancer Res . 2020 Sep 1;26(17):4468-4477
[PubMed ID: 32532790]
D'Angelo CR Ku K Gulliver J Chang J Intravascular large B-cell lymphoma presenting with altered mental status: A case report. World J Clin Oncol . 2019 Dec 24;10(12):402-408
[PubMed ID: 31890649]
Bartlett NL Wilson WH Jung SH Hsi ED Maurer MJ Pederson LD Polley MC Pitcher BN Cheson BD Kahl BS Friedberg JW Staudt LM Wagner-Johnston ND Blum KA Abramson JS Reddy NM Winter JN Chang JE Gopal AK Chadburn A Mathew S Fisher RI Richards KL Schöder H Zelenetz AD Leonard JP Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol . 2019 Jul 20;37(21):1790-1799
[PubMed ID: 30939090]
Flinn IW van der Jagt R Kahl B Wood P Hawkins T MacDonald D Simpson D Kolibaba K Issa S Chang J Trotman J Hallman D Chen L Burke JM First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. J Clin Oncol . 2019 Apr 20;37(12):984-991
[PubMed ID: 30811293]
Straus DJ Jung SH Pitcher B Kostakoglu L Grecula JC Hsi ED Schöder H Popplewell LL Chang JE Moskowitz CH Wagner-Johnston N Leonard JP Friedberg JW Kahl BS Cheson BD Bartlett NL CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood . 2018 Sep 6;132(10):1013-1021
[PubMed ID: 30049811]
Byrd JC Ruppert AS Heerema NA Halvorson AE Hoke E Smith MR Godwin JE Couban S Fehniger TA Thirman MJ Tallman MS Appelbaum FR Stone RM Robinson S Chang JE Mandrekar SJ Larson RA Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv . 2018 Jul 24;2(14):1705-1718
[PubMed ID: 30030269]
Chang JE Carmichael LL Kim K Peterson C Yang DT Traynor AM Werndli JE Huie MS McFarland TA Volk M Blank J Callander NS Longo WL Kahl BS VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. Clin Lymphoma Myeloma Leuk . 2018 Jan;18(1):e61-e67
[PubMed ID: 29191715]
Abaza YM Kadia TM Jabbour EJ Konopleva MY Borthakur G Ferrajoli A Estrov Z Wierda WG Alfonso A Chong TH Chuah C Koh LP Goh BC Chang JE Durkes DE Foudray MC Kantarjian HM Dong XQ Garcia-Manero G Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer . 2017 Dec 15;123(24):4851-4859
[PubMed ID: 28841236]
Chang JE Maintenance lenalidomide could be most relevant after first-line therapy. Lancet Haematol . 2017 Nov;4(11):e502-e503
[PubMed ID: 28958468]
Advani RH Lebovic D Chen A Brunvand M Goy A Chang JE Hochberg E Yalamanchili S Kahn R Lu D Agarwal P Dere RC Hsieh HJ Jones S Chu YW Cheson BD Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clin Cancer Res . 2017 Mar 1;23(5):1167-1176
[PubMed ID: 27601593]
Chang JE Havighurst T Kim K Eickhoff J Traynor AM Kirby-Slimp R Volk LM Werndli J Go RS Weiss M Blank J Kahl BS Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study. Br J Haematol . 2016 Apr;173(2):283-91
[PubMed ID: 26913697]
Zent CS Victoria Wang X Ketterling RP Hanson CA Libby EN Barrientos JC Call TG Chang JE Liu JJ Calvo AR Lazarus HM Rowe JM Luger SM Litzow MR Tallman MS A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). Am J Hematol . 2016 Mar;91(3):308-12
[PubMed ID: 26662208]
Chang JE Li H Smith MR Gascoyne RD Paietta EM Yang DT Advani RH Horning SJ Kahl BS Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood . 2014 Mar 13;123(11):1665-73
[PubMed ID: 24458437]
Chang JE Kahl BS PI3-kinase inhibitors in chronic lymphocytic leukemia. Curr Hematol Malig Rep . 2014 Mar;9(1):33-43
[PubMed ID: 24390602]
Lake W Chang JE Kennedy T Morgan A Salamat S BaÅŸkaya MK A case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics. Neurosurgery . 2013 Jun;72(6):960-70; discussion 970
[PubMed ID: 23685504]
Chang JE Kahl BS Bendamustine for treatment of chronic lymphocytic leukemia. Expert Opin Pharmacother . 2012 Jul;13(10):1495-505
[PubMed ID: 22663160]
Chang JE Kahl BS Bendamustine: more ammunition in the battle against mantle cell lymphoma. Leuk Lymphoma . 2012 Jul;53(7):1249-50
[PubMed ID: 22220986]
Chang JE Kahl BS Current status of targeted therapies for mantle cell lymphoma. Drugs . 2011 Dec 3;71(17):2307-26
[PubMed ID: 22085387]
Leal T Chang JE Mehta M Robins HI Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment. Curr Cancer Ther Rev . 2011 Nov;7(4):319-327
[PubMed ID: 23251128]
Chang JE Peterson C Choi S Eickhoff JC Kim K Yang DT Gilbert LA Rogers ES Werndli JE Huie MS McFarland TA Volk M Blank J Callander NS Longo WL Kahl BS VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol . 2011 Oct;155(2):190-7
[PubMed ID: 21848883]